Letermovir Prophylaxis for CMV in Transplant Patients
This study is looking at a new way to use letermovir, a medicine that helps prevent cytomegalovirus (CMV) infections, in people who have had a hematopoietic cell transplant (HCT). The goal is to see if adjusting when you take letermovir, based on how your immune system responds to CMV, can better prevent infections compared to taking it continuously. You might be able to join if you've had an allogeneic HCT (transplant from a donor), have tested positive for CMV in the past, and are currently taking letermovir. The study will measure safety and side effects over about one year. The study is currently recruiting 105 participants.
- Study design
- This interventional study plans to enroll 105 participants. It compares two approaches to taking letermovir after a hematopoietic cell transplant.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety and adverse events through study completion, which is an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
At a glance
Conditions
NCT06639854
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The University of Texas MD Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Fareed Khawaja, MBBS · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs).Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0